Navigation Links
NeurogesX to Provide Qutenza® Launch Update
Date:2/9/2011

mmercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory neuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement

<
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX to Present at Two February Investor Conferences
2. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
3. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
4. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
5. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
6. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
7. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
8. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
9. NeurogesX Expands Commercial Operations Leadership Team
10. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
11. NeurogesX to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 24, 2014 ... Report on Global Disposable Syringe Industry of ... its online business intelligence library. ... Disposable Syringe Industry is a professional and ... market.  For overview analysis, the report introduces ...
(Date:12/24/2014)...  The American Diabetes Association is recommending a ... with diabetes and that all people with diabetes ... in keeping with recent changes to guidelines for ... of Cardiology (ACC) and American Heart Association (AHA). ... changes to the Association,s annual revised Standards of ...
(Date:12/24/2014)... Dec. 23, 2014  Medical Science Liaisons play a ... link between the medical device industry and key stakeholders, ... the coming years as the device industry relies on ... to research by benchmarking firm, Best Practices, LLC, one ... important edge is by harnessing new technology to enable ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... BEIJING, Oct. 28 /PRNewswire-Asia-FirstCall/ ... CMED ), a leading China-based medical device,company that ... announced that the Company will hold its annual ... 24 Yong Chang North Road,Beijing Economic-Technological Development Area, ...
... , SOUTH SAN FRANCISCO, Calif., Oct. 28 Rigel Pharmaceuticals, Inc. ... and chief executive officer, and Raul R. Rodriguez, executive vice president ... investor conferences in November. Details of each conference are as ... Waldorf Astoria, New York City, NY, ...
Cached Medicine Technology:China Medical Technologies to Hold its Annual General Meeting on November 16, 2009 2Rigel Announces Presentations at Two Investor Conferences 2
(Date:12/26/2014)... Cooking and warming equipment has ... This score reflects slightly positive negotiation conditions for buyers, ... switching costs and a low level of price volatility. ... of substitutes for cooking and warming equipment and high ... key inputs in the production process of this equipment,” ...
(Date:12/26/2014)... Plugin and template developers from Pixel Film Studios ... Cut Pro X. , “TransPack Volume 5 gives users the ... an industry professional look” Said Christina Austin, CEO of Pixel ... 5, a new level of professionalism will become the standard.” ... Final Cut Pro X transitions featuring organic animations. Choose from ...
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... and more people are falling prey to E. coli infection ... an HHMI international research scholar at the University// of British ... place a death grip on intestinal cells. Finlay's lab determined ... in development of a vaccine for humans, as well as ...
... seem to be at significantly greater risk of developing ... of print in the journal Gut. ,The ... 1250 of whom were identical. The twins completed a ... ever had IBS. ,This information was then ...
... bacteria are known as the agent involved in food ... worldwide. // However this bacterium invades by stealth and ... them. This is ironical since macrophages are the cells ... Salmonella escapes detection by macrophages, turning predator cells to ...
... the Government's announcement that there will be up to 23,000 junior ... Chair // of the Junior Doctor’s Committee [JDC], Dr Tom Dolphin, ... such a large increase in the indicative number of training posts, ... junior doctors. ,"We are still concerned about what happens ...
... physicians experienced with the technique//, and pain reduction is ... cohort study. ,Among the 25 patients enrolled in ... 10-point visual analog scale was 7.3 at baseline, 2.7 ... weeks, and 0.3 at 52 weeks, according to Michael ...
... women after consumption of raw oysters. Further probing revealed that ... ,Agriculture Commissioner Tommy Irvin commenting on the deaths said “The ... and they lost their lives.” In his opinion, raw oysters ... DeKalb Farmers’ Market reiterated that they have always been enabling ...
Cached Medicine News:Health News:Restricted Fetal Growth Increases Risk of Irritable Bowel Syndrome 2Health News:Salmonella Bacteria Are Deceptive 2Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 2Health News:Sacroplasty Safe and Effective to Reduce Low Back Pain 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: